Anti-microbial resistance (AMR) is one of the most pressing global health challenges of the 21st century. The World Health Organization has identified AMR as one of the top ten threats to global health, estimating that drug-resistant infections already cause approximately 1.27 million deaths annually and contribute to nearly 5 million deaths worldwide. By 2050, if left unchecked, AMR could cause 10 million deaths per year and cost the global economy up to $100 trillion. What is often overlooked in discussions about AMR is the critical role that pharmaceutical manufacturing, particularly API production, plays in both contributing to and combating this crisis.
AMR as a Global Health Threat
Anti-microbial resistance occurs when bacteria, viruses, fungi, and parasites evolve to become resistant to the drugs designed to kill them. This natural evolutionary process is accelerated by several human activities, including the overuse and misuse of antibiotics in human medicine and agriculture, inadequate infection prevention and control practices, limited access to clean water and sanitation, and importantly, the release of anti-microbial compounds into the environment through pharmaceutical manufacturing effluents.
The consequences of AMR are already visible. Common infections that were once easily treatable are becoming difficult or impossible to cure. Surgical procedures and cancer chemotherapy, which rely on effective antibiotics to prevent infection, become riskier as resistance increases. The development pipeline for new antibiotics is thin, with few novel classes of antibiotics in development and limited commercial incentive for pharmaceutical companies to invest in anti-microbial research.
How API Manufacturing Can Contribute to AMR
The pharmaceutical manufacturing process, particularly API production for anti-microbial drugs, can contribute to AMR in several ways.
Effluent discharge from API manufacturing facilities is perhaps the most direct pathway. When wastewater containing active anti-microbial compounds is discharged into the environment, whether into rivers, groundwater, or soil, it creates conditions that promote the development of resistant organisms. Bacteria exposed to sub-therapeutic concentrations of antibiotics in the environment are subjected to selective pressure that favors the survival and proliferation of resistant strains.
Studies have found alarming concentrations of antibiotics in waterways near pharmaceutical manufacturing clusters. In some locations, environmental concentrations of antibiotics exceed the minimum inhibitory concentrations (MICs) needed to kill susceptible bacteria, creating ideal conditions for resistance selection. Research published in peer-reviewed journals has documented the presence of multi-drug resistant bacteria in water bodies downstream from API manufacturing facilities in various countries.
Substandard APIs present another pathway to AMR. APIs that do not meet quality specifications for purity or potency can result in finished products that deliver sub-therapeutic doses of antibiotics to patients. Sub-therapeutic dosing is one of the primary drivers of resistance development in clinical settings, as it exposes bacteria to drug levels that are high enough to create selective pressure but not high enough to kill the target organisms.
Improper waste management of API manufacturing by-products, including spent solvents, mother liquors, and reject batches, can release anti-microbial compounds into the environment if not handled according to proper disposal protocols.
Responsible Manufacturing Practices
Addressing the manufacturing-related drivers of AMR requires a comprehensive approach that spans environmental management, quality assurance, and industry governance.
Effluent treatment is the most critical intervention. API manufacturers producing anti-microbial compounds must implement advanced wastewater treatment systems capable of reducing antibiotic concentrations in discharged effluent to levels that do not promote resistance. This typically requires multi-stage treatment including biological treatment, advanced oxidation processes, and activated carbon adsorption. Some leading manufacturers have adopted zero liquid discharge (ZLD) systems that eliminate wastewater discharge entirely.
Predicted No-Effect Concentrations (PNECs) for anti-microbial compounds provide science-based targets for effluent quality. The AMR Industry Alliance and academic researchers have published PNECs for common antibiotics, establishing maximum allowable environmental concentrations that are not expected to promote resistance. Progressive manufacturers are adopting these PNECs as discharge limits, going beyond what local regulations may require.
Quality management systems that ensure consistent API quality are essential for preventing substandard products from reaching patients. Robust in-process controls, validated manufacturing processes, and comprehensive finished product testing all contribute to ensuring that every batch of anti-microbial API meets its specifications for purity and potency.
Waste management protocols for anti-microbial manufacturing waste must ensure that reject materials, spent solvents, and other waste streams containing active anti-microbial compounds are properly treated or destroyed rather than released into the environment. High-temperature incineration and chemical neutralization are among the accepted disposal methods.
Supply chain transparency allows downstream buyers and regulators to verify that anti-microbial APIs are manufactured under conditions that minimize AMR risk. Progressive companies are publishing environmental performance data and accepting third-party audits of their environmental management systems.
Regulatory Frameworks
Several regulatory and industry initiatives are addressing the manufacturing dimensions of AMR.
The AMR Industry Alliance, a coalition of more than 100 pharmaceutical and biotech companies, has developed a common framework for responsible antibiotic manufacturing. The Alliance published a common antibiotic manufacturing standard that includes PNEC-based discharge limits and environmental management requirements. Member companies commit to applying these standards across their supply chains.
The Pharmaceutical Supply Chain Initiative (PSCI) includes environmental requirements in its Principles for Responsible Supply Chain Management. PSCI members, which include many of the world’s largest pharmaceutical companies, are expected to apply these principles to their API suppliers.
National regulatory initiatives are emerging in several countries. The European Union has proposed regulations requiring environmental risk assessments for pharmaceutical manufacturing facilities. India’s Central Pollution Control Board (CPCB) and State Pollution Control Boards enforce environmental discharge standards, though implementation and enforcement vary.
The G7 and G20 have both recognized the role of pharmaceutical manufacturing in AMR and called for improved environmental standards for antibiotic production. These high-level endorsements create political momentum for regulatory action.
India’s Efforts to Combat AMR
As the world’s largest producer of generic antibiotics, India has a particular responsibility and opportunity in addressing manufacturing-related AMR risks.
The Indian government has taken several steps. The National Action Plan on Antimicrobial Resistance, launched in 2017, includes objectives related to pharmaceutical manufacturing and environmental management. The CPCB has issued guidelines for pharmaceutical effluent treatment, and several state governments have strengthened enforcement of discharge standards.
Industry-led initiatives are also gaining momentum. Several major Indian API manufacturers have invested in advanced effluent treatment systems, and some have achieved zero liquid discharge capabilities. Industry associations, including the Indian Drug Manufacturers’ Association (IDMA) and the Bulk Drug Manufacturers Association (BDMA), have advocated for improved environmental standards and supported capacity building for smaller manufacturers.
Challenges remain, particularly for small and medium-sized manufacturers who may lack the financial resources to invest in advanced effluent treatment. Government incentives, industry collaboration, and technology transfer programs can help address this gap.
The Role of Quality Testing
Quality testing plays a dual role in combating AMR. At the product level, rigorous quality testing ensures that anti-microbial APIs meet their specifications, preventing substandard products from reaching patients. At the environmental level, testing of effluents and environmental samples monitors whether manufacturing activities are releasing anti-microbial compounds at levels that could promote resistance.
Key quality parameters for anti-microbial APIs include assay (potency), ensuring the API contains the correct amount of active compound. Related substances testing identifies and quantifies impurities that could affect product quality. Microbiological testing verifies that the API itself is not contaminated with resistant organisms. Dissolution testing (for finished products) ensures adequate drug release and absorption.
Environmental monitoring should include testing of wastewater before and after treatment, monitoring of receiving water bodies, and periodic assessment of resistance patterns in environmental bacterial populations.
What Buyers Should Look For
Global pharmaceutical buyers sourcing anti-microbial APIs have both the opportunity and the responsibility to drive improved AMR practices through their procurement decisions.
Environmental management credentials should be evaluated as part of supplier qualification. Look for manufacturers with advanced effluent treatment systems, documented environmental monitoring programs, and third-party environmental audits or certifications.
AMR Industry Alliance membership or adherence to the Alliance’s manufacturing standard provides a useful indicator of a supplier’s commitment to responsible anti-microbial manufacturing.
Transparency and reporting on environmental performance demonstrates a supplier’s willingness to be held accountable. Request environmental performance data as part of regular supplier review processes.
Quality track record for anti-microbial APIs, including batch consistency data, regulatory inspection history, and any product quality complaints, should be thoroughly evaluated.
Commitment to continuous improvement in both product quality and environmental management signals a supplier that takes AMR seriously as a long-term challenge rather than a compliance checkbox.
Key Takeaways
- AMR causes approximately 1.27 million deaths annually and could reach 10 million per year by 2050
- API manufacturing contributes to AMR through effluent discharge, substandard product quality, and improper waste management
- Responsible manufacturing requires advanced effluent treatment, PNEC-based discharge limits, robust quality systems, and supply chain transparency
- Regulatory frameworks including the AMR Industry Alliance standard and national regulations are evolving to address manufacturing-related AMR risks
- India is taking steps to address AMR in pharmaceutical manufacturing but challenges remain for smaller manufacturers
- Buyers can drive improvement by incorporating environmental and quality criteria into supplier qualification and procurement decisions
At KP Life Science, we recognize that responsible pharmaceutical manufacturing is inseparable from the fight against anti-microbial resistance. We work with manufacturing partners who demonstrate strong environmental management practices and a commitment to producing anti-microbial APIs that meet the highest quality standards. Combating AMR is a shared responsibility, and our sourcing practices reflect that commitment.